Pub Date : 2026-03-01Epub Date: 2025-11-28DOI: 10.1016/j.remnie.2025.500261
R. Caratini , A. Segarra , E. Garcia , K. Quintero , J. Cordon , M. Vega , J. Cases , I. Cebrecos , J. Ribera-Perianes , S. Vidal-Sicart
This work presents the key aspects of the sentinel lymph node biopsy (SLNB) procedure in breast cancer, based on the protocol used at Hospital Clínic de Barcelona. The aim is to facilitate its generalization in other hospital settings and training environments, promoting the standardization of the technique. It is also intended to serve as a useful resource for resident physicians and other medical trainees.
这项工作提出了乳腺癌前哨淋巴结活检（SLNB）程序的关键方面，基于Clínic de Barcelona医院使用的协议。目的是促进其在其他医院设置和培训环境的推广，促进技术的标准化。它还旨在为住院医师和其他医疗培训生提供有用的资源。
{"title":"SUMMARY: Selective Sentinel Lymph Node Biopsy (SSLNB) in breast cancer for residents","authors":"R. Caratini , A. Segarra , E. Garcia , K. Quintero , J. Cordon , M. Vega , J. Cases , I. Cebrecos , J. Ribera-Perianes , S. Vidal-Sicart","doi":"10.1016/j.remnie.2025.500261","DOIUrl":"10.1016/j.remnie.2025.500261","url":null,"abstract":"<div><div>This work presents the key aspects of the sentinel lymph node biopsy (SLNB) procedure in breast cancer, based on the protocol used at Hospital Clínic de Barcelona. The aim is to facilitate its generalization in other hospital settings and training environments, promoting the standardization of the technique. It is also intended to serve as a useful resource for resident physicians and other medical trainees.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500261"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145650268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-08-30DOI: 10.1016/j.remnie.2025.500210
S. de la Torre Fernández, A.K. Minguillan Van Kapel, B. Aradas Cabado, M.J Tello Galán, A.E. Seva Delgado, C.M. Hernández Heredia
{"title":"Portal of entry for Streptococcus gallolyticus in infective endocarditis","authors":"S. de la Torre Fernández, A.K. Minguillan Van Kapel, B. Aradas Cabado, M.J Tello Galán, A.E. Seva Delgado, C.M. Hernández Heredia","doi":"10.1016/j.remnie.2025.500210","DOIUrl":"10.1016/j.remnie.2025.500210","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500210"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-09-12DOI: 10.1016/j.remnie.2025.500229
A. Díaz Silván , D. Cabello García , L.F. Otón Sánchez
Objective
To determine the prognostic value of [18F]FDG PET/CT in follicular lymphoma (FL) patients in our routine clinical practice.
Material and methods
Retrospective study of FL patients assessed with PET/CT in our centre from 01/06/2008 to 01/06/2020. This study aimed to investigate the prognostic value of quantitative parameters (MTV, TLG, ΔSUV max) and qualitative criteria (Lugano classification), and its relationships with progression-free survival (PFS) and overall survival (OS).
Results
Among patients with available staging PET/CT, the 5-year OS was 90.4% for those with lower MTV and 89.7% for those with higher MTV (p = 0.3). The PFS was 77.6% for those with lower MTV and 53.2% for those with higher MTV (p = 0.001). TLG yielded statistically similar results.
A ΔSUV max ≥ 66% was associated with higher OS and PFS at 5 years, at both interim and final PET/CT studies (iPET and fPET). The 5-year OS for patients with complete metabolic response was 86.3% in iPET and 89.0% in fPET, compared to 84.1% and 79.0%, respectively, for those positive in iPET (p = 0.3) and fPET (p = 0.1). The 5-year PFS for patients with complete metabolic response was 76.9% in iPET and 73.1% in fPET, compared to 58.7% and 62.2%, respectively, for those positive in iPET (p = 0.04) and fPET (p = 0.09).
Conclusions
PET/CT is valuable as a prognostic factor in FL, both during staging (providing parameters with independent prognostic value such as MTV and TLG) and during and after treatment (as it correlates with survival).
{"title":"Prognostic value of [18F]FDG PET/CT in follicular lymphoma","authors":"A. Díaz Silván , D. Cabello García , L.F. Otón Sánchez","doi":"10.1016/j.remnie.2025.500229","DOIUrl":"10.1016/j.remnie.2025.500229","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the prognostic value of [<sup>18</sup>F]FDG PET/CT in follicular lymphoma (FL) patients in our routine clinical practice.</div></div><div><h3>Material and methods</h3><div>Retrospective study of FL patients assessed with PET/CT in our centre from 01/06/2008 to 01/06/2020. This study aimed to investigate the prognostic value of quantitative parameters (MTV, TLG, ΔSUV max) and qualitative criteria (Lugano classification), and its relationships with progression-free survival (PFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>Among patients with available staging PET/CT, the 5-year OS was 90.4% for those with lower MTV and 89.7% for those with higher MTV (p = 0.3). The PFS was 77.6% for those with lower MTV and 53.2% for those with higher MTV (p = 0.001). TLG yielded statistically similar results.</div><div>A ΔSUV max ≥ 66% was associated with higher OS and PFS at 5 years, at both interim and final PET/CT studies (iPET and fPET). The 5-year OS for patients with complete metabolic response was 86.3% in iPET and 89.0% in fPET, compared to 84.1% and 79.0%, respectively, for those positive in iPET (p = 0.3) and fPET (p = 0.1). The 5-year PFS for patients with complete metabolic response was 76.9% in iPET and 73.1% in fPET, compared to 58.7% and 62.2%, respectively, for those positive in iPET (p = 0.04) and fPET (p = 0.09).</div></div><div><h3>Conclusions</h3><div>PET/CT is valuable as a prognostic factor in FL, both during staging (providing parameters with independent prognostic value such as MTV and TLG) and during and after treatment (as it correlates with survival).</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500229"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-09-23DOI: 10.1016/j.remnie.2025.500232
L. Rodríguez-Díaz , P. Zaragoza-Ballester , I. Torras , E. Mensión , I. Cebrecos , X. Cases , M. Vega , J. Cordón , J. Ribera-Perianes , S. Vidal-Sicart , on behalf of the Clínic Barcelona Nuclear Medicine (CBNM) Group
Introduction and objectives
5–10% of breast tumor patients develop local breast tumor recurrence. The absence of axillary re-staging could increase future local recurrence and mortality risk in these patients. The lymphoscintigraphy for sentinel lymph node biopsy in recurrences (rSLNB) using a radiotracer injection, can be an option to evaluate axillar status, but other factors known to alter the usual behaviour of SLN migration have to be taken into account, such as previous axillary surgery, breast surgery or adjuvant treatments. Our objective was to evaluate the relationship between these factors and the success rate of rSLNB (overall and aberrant drainage rates, metastases ratio).
Materials and methods
1102 patients were retrospectively evaluated in a tertiary hospital between 10/2018–04/2022. 52 patients with ipsilateral breast tumor recurrence who underwent rSLNB were included. Demographic data, tumor characteristics, previous treatments, drainage rates and characteristics were collected and analyzed (R statistical software).
Results
Overall drainage rate was 83%, in which excision was performed in 91%. Overall migration rate was significantly higher in patients with previous SLNB (92% vs 60%, p-value = 0.012) and aberrant drainage was significantly higher in patients with previous axillar lymphadenectomy (ALND) (53% vs 24%, p-value = 0.047). No statistical differences were observed in breast surgery or adjuvant radiotherapy. The percentage of positivity found was 13% (3 micrometastases and 2 macrometastases). 20% of metastases were found in aberrant drainage territories.
Conclusions
rSLNB is a feasible and applicable technique in ipsilateral breast tumor recurrence, providing key information in locorregional recurrence management. A considerable percentage of metastases are located in aberrant drainage territories, which would have been missed without rSLNB. Therefore, rSLNB is essential for a correct axillary evaluation in order to trace them.
简介与目的：5-10%的乳腺肿瘤患者发生乳腺局部肿瘤复发。没有腋窝再分期可能增加这些患者未来的局部复发和死亡风险。使用放射性示踪剂注射进行复发前哨淋巴结活检（rSLNB）的淋巴显影可以作为评估腋窝状态的一种选择，但必须考虑其他已知的改变SLN迁移行为的因素，例如以前的腋窝手术、乳房手术或辅助治疗。我们的目的是评估这些因素与rSLNB成功率（总引流率和异常引流率，转移率）之间的关系。材料与方法：回顾性分析某三级医院2018年10月- 2022年4月收治的1102例患者。52例同侧乳腺肿瘤复发患者行rSLNB。收集统计学资料、肿瘤特征、既往治疗、引流率及特征（R统计软件）进行分析。结果：总引流率83%，切除率91%。既往SLNB患者的总体迁移率显著高于（92% vs 60%， p值= 0.012），既往腋窝淋巴结切除术（ALND）患者的异常引流率显著高于（53% vs 24%， p值= 0.047）。在乳房手术和辅助放疗方面无统计学差异。阳性比例为13%（微转移3例，大转移2例）。20%的转移灶位于异常引流区。结论：rSLNB在同侧乳腺肿瘤复发治疗中是一种可行、适用的技术，为局部或局部复发治疗提供了关键信息。相当大比例的转移灶位于异常引流区，如果没有rSLNB，这些转移灶可能会被遗漏。因此，rSLNB对于正确的腋窝评估是必不可少的，以便追踪它们。
{"title":"Selective sentinel lymph node biopsy in breast cancer local recurrence","authors":"L. Rodríguez-Díaz , P. Zaragoza-Ballester , I. Torras , E. Mensión , I. Cebrecos , X. Cases , M. Vega , J. Cordón , J. Ribera-Perianes , S. Vidal-Sicart , on behalf of the Clínic Barcelona Nuclear Medicine (CBNM) Group","doi":"10.1016/j.remnie.2025.500232","DOIUrl":"10.1016/j.remnie.2025.500232","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>5–10% of breast tumor patients develop local breast tumor recurrence. The absence of axillary re-staging could increase future local recurrence and mortality risk in these patients. The lymphoscintigraphy for sentinel lymph node biopsy in recurrences (rSLNB) using a radiotracer injection, can be an option to evaluate axillar status, but other factors known to alter the usual behaviour of SLN migration have to be taken into account, such as previous axillary surgery, breast surgery or adjuvant treatments. Our objective was to evaluate the relationship between these factors and the success rate of rSLNB (overall and aberrant drainage rates, metastases ratio).</div></div><div><h3>Materials and methods</h3><div>1102 patients were retrospectively evaluated in a tertiary hospital between 10/2018–04/2022. 52 patients with ipsilateral breast tumor recurrence who underwent rSLNB were included. Demographic data, tumor characteristics, previous treatments, drainage rates and characteristics were collected and analyzed (R statistical software).</div></div><div><h3>Results</h3><div>Overall drainage rate was 83%, in which excision was performed in 91%. Overall migration rate was significantly higher in patients with previous SLNB (92% vs 60%, p-value<!--> <!-->=<!--> <!-->0.012) and aberrant drainage was significantly higher in patients with previous axillar lymphadenectomy (ALND) (53% vs 24%, p-value<!--> <!-->=<!--> <!-->0.047). No statistical differences were observed in breast surgery or adjuvant radiotherapy. The percentage of positivity found was 13% (3 micrometastases and 2 macrometastases). 20% of metastases were found in aberrant drainage territories.</div></div><div><h3>Conclusions</h3><div>rSLNB is a feasible and applicable technique in ipsilateral breast tumor recurrence, providing key information in locorregional recurrence management. A considerable percentage of metastases are located in aberrant drainage territories, which would have been missed without rSLNB. Therefore, rSLNB is essential for a correct axillary evaluation in order to trace them.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500232"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-09-23DOI: 10.1016/j.remnie.2025.500208
E. Ozkan , B. Demir , C. Soydal , M. Araz , E. Dursun , N.O. Kucuk , Y. Urun
Purpose
In this study we aimed to investigate prediction of response with [68Ga]Ga-PSMA PET-derived parameters and the effectiveness of RECIP criteria and PSA response in predicting survival after [177Lu]Lu-PSMA therapy.
Methods
Patients who received at least 2 cycles of [177Lu]Lu-PSMA therapy were retrospectively included in the study. All lesions in the PET images were segmented and PSMA PET-based parameters were extracted. The treatment response was evaluated according to RECIP and PSA criteria. ROC analyses were performed to assess their discriminatory power in predicting response. Correlation of overall survival with RECIP and PSA-based response was evaluated using Kaplan-Meier survival analysis.
Results
A total of 41 patients were included in the study. SUVmax, SUVpeak, SUVmean, qPSG-max and qPSG-mean values were significant factors in predicting PSA response. However, in predicting RECIP response (CR + PR), the AUC values for the SUV parameters were not significantly higher than 0.5. In predicting RECIP disease control (CR + PR + SD), the AUC values for SUVmax, SUVpeak, and SUVmean were 0.742(p = 0.002), 0.742(p = 0.002), and 0.722(p = 0.006). In the RECIP-responder and non-responder groups, the median survival was 33.5 and 15.2 months (p = 0.005). In patients with RECIP-disease control and progressive disease, the median survival was 25.1 and 15.2 months (p = 0.002). However, the survival difference between PSA-responder and non-responders groups did not reach significance (p = 0.127).
Conclusion
PSMA PET imaging is a useful method to select patients who will most likely to benefit from [177Lu]Lu-PSMA treatment. Also, it has been shown that RECIP has significantly performed better than PSA-based response evaluation in terms of predicting overall survival.
{"title":"Prediction of [177Lu]Lu-PSMA-617 treatment response with [68Ga]Ga-PSMA-11 PET-derived variables and correlation of the overall survival with serum PSA and PSMA PET-based response criteria","authors":"E. Ozkan , B. Demir , C. Soydal , M. Araz , E. Dursun , N.O. Kucuk , Y. Urun","doi":"10.1016/j.remnie.2025.500208","DOIUrl":"10.1016/j.remnie.2025.500208","url":null,"abstract":"<div><h3>Purpose</h3><div>In this study we aimed to investigate prediction of response with [68Ga]Ga-PSMA PET-derived parameters and the effectiveness of RECIP criteria and PSA response in predicting survival after [177Lu]Lu-PSMA therapy.</div></div><div><h3>Methods</h3><div>Patients who received at least 2 cycles of [177Lu]Lu-PSMA therapy were retrospectively included in the study. All lesions in the PET images were segmented and PSMA PET-based parameters were extracted. The treatment response was evaluated according to RECIP and PSA criteria. ROC analyses were performed to assess their discriminatory power in predicting response. Correlation of overall survival with RECIP and PSA-based response was evaluated using Kaplan-Meier survival analysis.</div></div><div><h3>Results</h3><div>A total of 41 patients were included in the study. SUVmax, SUVpeak, SUVmean, qPSG-max and qPSG-mean values were significant factors in predicting PSA response. However, in predicting RECIP response (CR + PR), the AUC values for the SUV parameters were not significantly higher than 0.5. In predicting RECIP disease control (CR + PR + SD), the AUC values for SUVmax, SUVpeak, and SUVmean were 0.742(<em>p</em> = 0.002), 0.742(<em>p</em> = 0.002), and 0.722(<em>p</em> = 0.006). In the RECIP-responder and non-responder groups, the median survival was 33.5 and 15.2 months (<em>p</em> = 0.005). In patients with RECIP-disease control and progressive disease, the median survival was 25.1 and 15.2 months (<em>p</em> = 0.002). However, the survival difference between PSA-responder and non-responders groups did not reach significance (<em>p</em> = 0.127).</div></div><div><h3>Conclusion</h3><div>PSMA PET imaging is a useful method to select patients who will most likely to benefit from [177Lu]Lu-PSMA treatment. Also, it has been shown that RECIP has significantly performed better than PSA-based response evaluation in terms of predicting overall survival.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500208"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-09-12DOI: 10.1016/j.remnie.2025.500228
L. Zheng, B. Wang, T. Wu, W. Qu
Background
Parathyroid adenoma (PA) is the most common cause of primary hyperparathyroidism (PHPT). 99mTc-methoxyisobutylisonitrile (99mTc-MIBI) imaging is widely applied in PA diagnosis and location. However, since the individual heterogeneity and adenoma function differences, the diagnostic efficacy of 99mTc-MIBI imaging is limited, which often leads to misdiagnosis and even mistreatment of PA.
Methods
In the present study, we established a novel dynamic nomogram model to assist the nuclear imaging diagnosis of PA. A total of 96 PA patients, with 65 cases in the positive group and 31 cases in the negative group, were enrolled for further analyzing.
Results
Univariate analysis showed there were no statistically significant differences between the two groups in terms of gender, age, and adenoma location. The patients in the positive group had significantly higher levels in PTH, serum calcium, longest diameter and shortest diameter of adenoma, compared to those in the negative group. But the serum phosphorus levels were lower in the positive group than in the negative group. Binary logistic regression analysis indicated that serum phosphorus and adenoma longest diameter were independent positive predictors. The dynamic nomogram model was generated by R software and logistic regression analysis (https://zhenglong-1988.shinyapps.io/dynnomapp/). The receiver operating characteristics curve (ROC curve) analysis revealed that the cut-off probability for the model to diagnose PA was 59.1%, with AUC values of 0.965.
Conclusions
The novel dynamic nomogram diagnostic model integrating serum phosphorus levels and longest diameter could effectively improve the diagnostic accuracy of radionuclide imaging for PA.
{"title":"A dynamic nomogram model integrating serum phosphorus and longest diameter enhances diagnostic accuracy of 99mTc-MIBI imaging for parathyroid adenoma patients with elevated parathyroid hormone","authors":"L. Zheng, B. Wang, T. Wu, W. Qu","doi":"10.1016/j.remnie.2025.500228","DOIUrl":"10.1016/j.remnie.2025.500228","url":null,"abstract":"<div><h3>Background</h3><div>Parathyroid adenoma (PA) is the most common cause of primary hyperparathyroidism (PHPT). <sup>99m</sup>Tc-methoxyisobutylisonitrile (<sup>99m</sup>Tc-MIBI) imaging is widely applied in PA diagnosis and location. However, since the individual heterogeneity and adenoma function differences, the diagnostic efficacy of <sup>99m</sup>Tc-MIBI imaging is limited, which often leads to misdiagnosis and even mistreatment of PA.</div></div><div><h3>Methods</h3><div>In the present study, we established a novel dynamic nomogram model to assist the nuclear imaging diagnosis of PA. A total of 96 PA patients, with 65 cases in the positive group and 31 cases in the negative group, were enrolled for further analyzing.</div></div><div><h3>Results</h3><div>Univariate analysis showed there were no statistically significant differences between the two groups in terms of gender, age, and adenoma location. The patients in the positive group had significantly higher levels in PTH, serum calcium, longest diameter and shortest diameter of adenoma, compared to those in the negative group. But the serum phosphorus levels were lower in the positive group than in the negative group. Binary logistic regression analysis indicated that serum phosphorus and adenoma longest diameter were independent positive predictors. The dynamic nomogram model was generated by R software and logistic regression analysis (<span><span>https://zhenglong-1988.shinyapps.io/dynnomapp/</span><svg><path></path></svg></span>). The receiver operating characteristics curve (ROC curve) analysis revealed that the cut-off probability for the model to diagnose PA was 59.1%, with AUC values of 0.965.</div></div><div><h3>Conclusions</h3><div>The novel dynamic nomogram diagnostic model integrating serum phosphorus levels and longest diameter could effectively improve the diagnostic accuracy of radionuclide imaging for PA.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500228"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-09-01DOI: 10.1016/j.remnie.2025.500205
Y.B. Cayirli , U. Elboga , I. Dogan
Objective
This study aimed to assess the predictive value of metastatic distribution patterns on 68Ga-PSMA-11 PET/CT in patients with chemotherapy- and castration-resistant prostate cancer undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy.
Materials and methods
A retrospective analysis was conducted on 48 patients who received ¹⁷⁷Lu-PSMA-617 therapy between April 2019 and August 2023. Demographic, clinical, and laboratory data, along with pre- and post-treatment 68Ga-PSMA-11 PET/CT images, were evaluated for associations with molecular response and progression. Whole-body PET/CT segmentation was performed using METAVOL software. Treatment response was classified using RECIP 1.0 criteria, and predictive values were analyzed using SPSS 22.0, with statistical significance set at p < 0.05.
Results
Based on RECIP 1.0 criteria, 58.3% (n = 28) responded to therapy, while 41.7% (n = 20) did not. Disease progression was observed in 29.2% (n = 14), and 70.8% (n = 34) showed no progression. Molecular response was significantly associated with parotid SUVmean (OR = 1.137, p = 0.047) and highest miM1 stage (OR = 0.241, p = 0.046). Molecular progression was significantly associated with lymph node metastasis (OR = 0.144, p = 0.006), bone-only metastasis (OR = 4.333, p = 0.030), ln/metTL-PSMA ratio (OR = 0.070, p = 0.042), b/metTL-PSMA ratio (OR = 13.085, p = 0.040), and TL-PSMA-based lymph node dominance over bone metastases (OR = 0.385, p = 0.044).
Conclusion
This study highlights the predictive value of metastatic burden distribution on 68Ga-PSMA PET/CT in determining treatment outcomes of ¹⁷⁷Lu-PSMA therapy.
目的：本研究旨在评估68Ga-PSMA-11 PET/CT在接受¹⁷Lu-PSMA-617放射配体治疗的化疗和去势抵抗性前列腺癌患者转移分布模式的预测价值。材料和方法：对2019年4月至2023年8月期间接受¹⁷Lu-PSMA-617治疗的48例患者进行回顾性分析。人口统计学、临床和实验室数据，以及治疗前后的68Ga-PSMA-11 PET/CT图像，评估与分子反应和进展的关系。使用METAVOL软件进行全身PET/CT分割。采用RECIP 1.0标准对治疗反应进行分类，并采用SPSS 22.0软件对预测值进行分析，差异有统计学意义(p)。结果：根据RECIP 1.0标准，58.3% （n = 28）患者对治疗有反应，41.7% （n = 20）患者对治疗无反应。29.2% （n = 14）患者出现疾病进展，70.8% （n = 34）患者无进展。分子反应与腮腺SUVmean （OR = 1.137, p = 0.047）和最高miM1分期（OR = 0.241, p = 0.046）显著相关。分子进展与淋巴结转移（OR = 0.144, p = 0.006）、骨转移（OR = 4.333, p = 0.030）、ln/metTL-PSMA比值（OR = 0.070, p = 0.042）、b/metTL-PSMA比值（OR = 13.085, p = 0.040）、tl - psma为基础的淋巴结优于骨转移（OR = 0.385, p = 0.044）显著相关。结论：该研究强调了68Ga-PSMA PET/CT转移负担分布在决定¹⁷Lu-PSMA治疗结果中的预测价值。
{"title":"Predictive value of metastatic distribution patterns on [68Ga]Ga-PSMA PET/CT for [177Lu]Lu-PSMA therapy","authors":"Y.B. Cayirli , U. Elboga , I. Dogan","doi":"10.1016/j.remnie.2025.500205","DOIUrl":"10.1016/j.remnie.2025.500205","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to assess the predictive value of metastatic distribution patterns on <sup>68</sup>Ga-PSMA-11 PET/CT in patients with chemotherapy- and castration-resistant prostate cancer undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy.</div></div><div><h3>Materials and methods</h3><div>A retrospective analysis was conducted on 48 patients who received ¹⁷⁷Lu-PSMA-617 therapy between April 2019 and August 2023. Demographic, clinical, and laboratory data, along with pre- and post-treatment <sup>68</sup>Ga-PSMA-11 PET/CT images, were evaluated for associations with molecular response and progression. Whole-body PET/CT segmentation was performed using METAVOL software. Treatment response was classified using RECIP 1.0 criteria, and predictive values were analyzed using SPSS 22.0, with statistical significance set at p < 0.05.</div></div><div><h3>Results</h3><div>Based on RECIP 1.0 criteria, 58.3% (n = 28) responded to therapy, while 41.7% (n = 20) did not. Disease progression was observed in 29.2% (n = 14), and 70.8% (n = 34) showed no progression. Molecular response was significantly associated with parotid SUVmean (OR = 1.137, p = 0.047) and highest miM1 stage (OR = 0.241, p = 0.046). Molecular progression was significantly associated with lymph node metastasis (OR = 0.144, p = 0.006), bone-only metastasis (OR = 4.333, p = 0.030), ln/metTL-PSMA ratio (OR = 0.070, p = 0.042), b/metTL-PSMA ratio (OR = 13.085, p = 0.040), and TL-PSMA-based lymph node dominance over bone metastases (OR = 0.385, p = 0.044).</div></div><div><h3>Conclusion</h3><div>This study highlights the predictive value of metastatic burden distribution on <sup>68</sup>Ga-PSMA PET/CT in determining treatment outcomes of ¹⁷⁷Lu-PSMA therapy.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500205"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-23DOI: 10.1016/j.remnie.2026.500267
J Serrano Vicente
{"title":"The Spanish Society of Nuclear Medicine and Molecular Imaging's position on preparing the health system for new Alzheimer's disease treatments.","authors":"J Serrano Vicente","doi":"10.1016/j.remnie.2026.500267","DOIUrl":"10.1016/j.remnie.2026.500267","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500267"},"PeriodicalIF":0.0,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号